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Human embryonic stem cells (hESC) have emerged as attractive candidates for cell-based therapies that are capable
of restoring lost cell and tissue function. These unique cells are able to self-renew indefinitely and have the capacity
to differentiate in to all three germ layers (ectoderm, endoderm and mesoderm). Harnessing the power of these
pluripotent stem cells could potentially offer new therapeutic treatment options for a variety of medical conditions.
Since the initial derivation of hESC lines in 1998, tremendous headway has been made in better understanding
stem cell biology and culture requirements for maintenance of pluripotency. The approval of the first clinical trials
of hESC cells for treatment of spinal cord injury and macular degeneration in 2010 marked the beginning of a new
era in regenerative medicine. Yet it was clearly recognized that the clinical utility of hESC transplantation was still
limited by several challenges. One of the most immediate issues has been the exposure of stem cells to animal
pathogens, during hESC derivation and during in vitro propagation. Initial culture protocols used co-culture with
inactivated mouse fibroblast feeder (MEF) or human feeder layers with fetal bovine serum or alternatively serum
replacement proteins to support stem cell proliferation. Most hESC lines currently in use have been exposed to
animal products, thus carrying the risk of xeno-transmitted infections and immune reaction. This mini review provides a
historic perspective on human embryonic stem cell culture and the evolution of new culture models. We highlight the
challenges and advances being made towards the development of xeno-free culture systems suitable for therapeutic
applications.
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Human embryonic stem cells (hESCs) have emerged as
exciting candidates for cell therapies in regenerative
medicine due to their capacity to self-renew and differ-
entiate into lineages of all three embryonic germ layers.
Studies have demonstrated the ability of hESCs to differ-
entiate into a number of pathologically relevant cell types,
including insulin-producing cells [1], neural precursor
cells [2], cardiomyocytes [3], and hepatocyte-like cells [4],
highlighting their potential to be used as a renewable cell
source to treat major diseases such as type I diabetes, Par-
kinson’s disease, cardiovascular disease and liver diseases,
among many others. Significant research efforts have thus* Correspondence: desain@ccf.org
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unless otherwise stated.been put towards human pluripotent stem cell research
for advancements in drug development, cell regeneration
and delivery of gene therapies. To reach the full thera-
peutic potential of hESCs, defined and reproducible cul-
ture systems must be integrated in order to generate
quantities of hESCs and their derivatives that are able to
sustain therapeutic applications.
Early studies with human ESCs involved direct culture
on mouse embryonic fibroblast feeder cells (MEFs) or
animal derived extracellular matrices with conditioned
medium from MEF feeder cells in medium supple-
mented with fetal bovine serum (FBS) [5,6]. This expos-
ure to non-human (xeno) cells and biologics left hESCs
vulnerable to xeno-contamination and immune rejec-
tion, ultimately rendering many of the existing hESC
lines unsuitable for clinical transplantation. This minihis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bryonic stem cell culture and the evolution of xeno-free
culture systems that will ultimately advance the develop-
ment of clinical grade hESC lines suitable for therapeutic
applications.
Review
Human pluripotent cells (hPSCs) include not only em-
bryonic stem cells (hESC) but also human induced pluri-
potent cells (hiPSCs). The latter are derived from adult
somatic cells that have been reprogrammed genetically
to behave like embryonic stem cells, expressing genes
necessary to maintain pluripotency. They represent an
additional valuable source of stem cells for therapeutic
use as they have the potential to differentiate in to any
cell lineage. Although this mini-review concentrates on
embryo-derived stem cells many of the described culture
systems have also been applied to hiPSCs.
Properties of human embryonic stem cells
The functional definition of embryonic stem cells
includes four criteria: 1) Origin from a pluripotent cell
population 2) Capable of self-renewal indefinitely in the
undifferentiated state 3) Capable of maintaining normal
karyotype during growth 4) Clonally derived cells cap-
able of differentiation in to all three embryonic germ
layers in vitro or in to teratomas in vivo. In culture,
hESC appear as tightly packed colonies with distinct
borders. Within the colonies, individual stem cells have
a high nucleus: cytoplasm ratio with distinctive nucleoli.
Human stem cell identification and characterization
in vitro also includes demonstration of a high level of al-
kaline phosphatase activity and expression of specific
embryonic stem cell markers [7]. The pluripotent hESCs
express transcription factors Oct 4, Nanog and Sox 2 as
well as tumor rejection antigens Tra–1–81 and Tra–1–60.
They are also strongly positive for stage-specific-
embryonic antigens SSEA 3 and SSEA 4 but negative for
SSEA 1. It is important that any newly derived hESC
line be rigorously tested to unequivocally identify it as
pluripotent. This should also include demonstration of
differentiation capability and positive identification of
all three germ layers in embryoid bodies formed in vitro
or by teratoma formation in vivo. Karyotypic stability
during culture needs also to be established.
Derivation of human embryonic stem cell lines
Human embryonic stem cells are typically derived from
the inner cell mass (ICM) of blastocyst stage embryos.
These unique cells can continuously proliferate and also
differentiate in to all three embryonic germ layers. The
establishment of the first hESC lines [5] provided the
impetus for the derivation of over a thousand of other
hESC lines, worldwide [8]. Human embryonic stem celllines have been derived from the inner cell mass (ICM)
of fresh as well as frozen blastocyst stage embryos. The
pluripotent ICM can be isolated via mechanical dissec-
tion [9,10], laser dissection [11,12] or immunosurgery
[5,13,14]. In the latter technique, polyclonal anti-human
serum combined with complement mediated lysis using
guinea pig serum is used to selectively lyse trophectoder-
mal cells, leaving behind only the ICM. This immunosur-
gery technique is perhaps the least suitable for generation
of clinical grade hESC lines since it involves the use of
non-human antibodies and proteins. Strom et al. suc-
cessfully derived hESC lines from ICM isolated by micro
dissection of human blastocysts using fine needles.
Laser-assisted biopsy of the blastocyst is however emer-
ging as the most promising technique for xeno-free iso-
lation of the ICM [12,15]. Subsequent to ICM isolation,
the pluripotent stems cells are plated and cultivated to
generate the ESC line. Methodologies for propagation of
these isolated pluripotent stem cells have included feeder
layers, extracellular matrices, proteins/peptides as well as
synthetic polymers.
The destruction of embryos for ICM isolation has
however raised ethical concerns [16]. An innovative al-
ternate approach has been generating hESC lines from
single blastomeres biopsied from patient embryos as is
routinely done during preimplantation genetic testing
(PGD) [17-19]. Chung et al. successfully derived 5 hu-
man ESC lines from a single blastomere biopsied from
individual eight cell embryos [17]. The single blastomere
was co-cultured with the parental biopsied embryo for
up to 24 hours before moving to blastocyst medium
containing fibronectin and laminin. The biopsied paren-
tal embryo remained available for clinical use after culti-
vation to the blastocyst stage. The presence of laminin
was noted to be critical for formation of ESC-like aggre-
gates and prevention of trophectoderm-like vesicles.
During stem cell derivation in serum-free media, inclu-
sion of FGF increased cloning efficiency, sustained cell
proliferation and was necessary to prevent differentiation
of hESC [20,21].
Efficiency of human ESC line generation from individ-
ual blastomeres has been variable dependent not only on
culture conditions to retain “plasticity” or totipotency of
the isolated blastomere but also on properties of the iso-
lated blastomere and the embryonic cell stage of isola-
tion. Early efforts to generate ESC lines from morula
stage embryos were unfruitful mostly resulting in aggre-
gates of trophoblast-like cells. Blastomere isolation from
embryos at earlier cell stages (4 and 8-cells) before cell
polarization into outer TE cells and inner non-polarized
cells destined to become the ICM were more successful.
Initial reports suggested that hESC lines derived from
different developmental stages possessed distinct gene
expression profiles. More recent data however, demonstrate
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preserve a similar pluripotent phenotype, regardless of the
source of derivation, ie. ICM-derived hESC and blastomere
derived hESC. Slight differences in both the molecular and
phenotypic profiles observed between cell lines are most
likely attributed to minor differences in derivation and cul-
ture protocols [22,23].
Culture systems for embryonic stem cell propagation
Feeder cell monolayers
Co-culture of isolated stem cells with mouse embryonic
fibroblasts (MEFs) was the first technique used for suc-
cessful establishment of hESC lines [5,14]. These initial
hESC lines were derived from ICM’s isolated from hu-
man blastocysts using immunosurgery. Growth factors
and cytokines secreted by MEF cells were found to be
necessary to maintain the pluripotent state of the stem
cells through repeated passages and time in culture. Hu-
man stem cell lines were shown to express the transcrip-
tion factor Oct-4 associated with pluripotency of the
ICM and down regulated upon cell differentiation [14].
These first successful demonstrations of hESC line der-
ivation using mouse feeder layers have served as the
basis for understanding stem cell biology and culture re-
quirements for maintenance of pluripotency.
The transmission of animal-derived infectious patho-
gens associated with MEFs remains however a critical
concern that precludes the use of current hESC lines for
clinical transplantation purposes. MEF cells can contain
viral particles capable of infecting humans [24]. Also
problematic is the use of bovine serum in these systems,
potentially exposing the cell line to prion transmission
as well as bovine viruses [25]. Transmission of xeno-
derived molecules can also occur through membrane de-
rived micro vesicles that typically function in cell: cell
communication [26,27]. Any pathogenic molecules taken
up in to the microvesicles would be capable of contamin-
ating the entire hESC culture. This problem may persist
even if cells are later transitioned to a feeder-free and
animal-protein free culture system. The self-renewing cap-
acity of stem cells demands stringent controls during
therapeutic use since cells from a single hESC line could
potentially be transplanted into many patients, increasing
the risk of inadvertently transmitting infectious pathogens
to a large patient population. Bioactive molecules such as
non-human sialic acid Neu5GC found in mouse feeders
as well as animal-derived serum products can also present
a problem. This animal derived sialic acid can be metabol-
ically incorporated on to the cell surface of hESCs [28].
Since humans have circulating antibodies to Neu5GC,
this raises the risk of an immune response after hESC
transplantation.
Human feeder layers for hESC culture were therefore
explored as a first step towards the ultimate goal ofxeno-free culture models. To this end a variety of differ-
ent human cell types such as human fallopian tube cells
[29], fetal foreskin [30], fetal muscle and skin [31], trans-
genic fetal liver stromal cells [32], bone marrow [33],
umbilical cord [34], placental cells [35,36] and endomet-
rial cells [37-39] have been tested for ability to support
stem cell renewal. From these studies it was clear that
both fetal and adult cells could be successively used. The
human umbilical stromal cell culture model offers a
large source of cells that can be collected noninvasively
and side-steps some of the ethical concerns raised with
the use of fetal foreskin, muscle or bone marrow derived
feeder layers. The use of established cell lines as feeders
rather than primary cultures may be less labor-intensive
and allows more consistency in feeder layer preparation.
New hESC lines have been derived and propagated using
a commercially available human foreskin fibroblast
(HFF) line [40,41]. Undifferentiated hESC growth in
xeno-free culture media for over 80 passages was pos-
sible with this HFF feeder [41,42]. Endometrial cells with
their unique role in supporting ICM proliferation and
pluripotency in vivo, also proved to be effective for
in vitro culture of stem cells [38,39,43]. Autogenic feeder
layers derived from the human stem cell line being
cultured was another interesting approach [44,45]. Such
culture systems entirely eliminated the risk of allogeneic
pathogen contamination from a donor feeder layer. Chen
et al. [44] generated fibroblast-like cells from the commer-
cially available H9 hESC line and went on to use these cul-
tures as a feeder layer for cultivation of the H9 stem cells.
Indirect co-culture by separating hESC from the feeder
cell population with a microporous membrane also proved
successful and reduced the risk of cross-contamination
[43,46].
These early studies with feeder layers have contributed
much to our understanding of the behavior, characteristics
and conditions necessary for stem cell renewal in vitro.
Basic fibroblast growth factor (bFGF) was determined to
be a key growth factor for maintaining hESC pluripotency
and shown to be endogenously produced by human feeder
cells used for hESC culture [32,47,48]. During stem cell
derivation in the absence of serum, inclusion of bFGF in-
creased cloning efficiency from single blastomeres, sus-
tained cell proliferation and was necessary to prevent
differentiation of hESC [20,21]. bFGF supports hESC re-
newal by promoting expression of IGF-II, TGFβ and Acti-
vin A (a member of the TGFβ superfamily) [49]. TGFβ
and Activin A signaling modulate cell fate decisions in the
early embryo and are involved in maintaining the pluripo-
tency of inner cell mass cells [49-54]. Conditioned
medium from feeder cells contain high levels of Activin A
[51]. Hongisto et al. showed that feeder cell expression of
a specific isoform of laminin (LM-511) was associated
with its functionality in supporting hESC [55].
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dependent hESC culture systems have many limita-
tions that make them unsuitable for future therapeutic
applications. Maintenance of feeder layers is very labor
intensive with lot-to-lot inconsistencies between feeder
populations. This variation can ultimately affect the
stem cells as well as their downstream differentiation
in to specific cell types for clinical therapy.
Feeder-free culture systems
The focus of current stem cell research has been the de-
sign of feeder-free, xeno-free culture systems with chem-
ically defined media formulations. We present some of the
most relevant studies in the ensuing sections. Tables 1 and
2 summarize the more recent work on hESC culture and
contrast the different culture systems. Systems classified
as “xeno-free” will likely prove the most attractive for
future clinical therapeutic applications.
Extracellular matrix and cell adhesion molecules One
of the first approaches tested for feeder-free growth re-
lied on the use of extracellular matrix proteins in com-
bination with growth factor supplementation to create
an in vitro microenvironment that promoted stem cell
renewal. The extracellular matrix, Matrigel isolated from
mouse Engelbreth-Holm-Swarm teratocarcinoma cells
was used by Xu et al. [6] as a feeder cell substitute for
hESC culture. Matrigel is a gelatinous mixture of colla-
gen IV, laminin, proteoglycans, entactin and other
growth factors [56]. To date Matrigel, often in combin-
ation with growth factors or conditioned medium from
feeder cultures has been the most frequently used sys-
tem for hESC culture [57-63]. Lot-to-lot variations in
the Matrigel composition can however pose problems,
inhibiting its effectiveness in maintaining cells in a pluri-
potent state, thus affecting reproducibility of subsequent
stem cell differentiation protocols. The use of Matrigel
also raises clinical concerns as certain batches have been
found to be contaminated with the single stranded
mouse RNA virus, Lactate Dehydrogenase Elevating
Virus (LDEV), ultimately questioning the safety of using
stem cells that have been cultured on animal derived
extracellular matrix in a therapeutic setting [64].
Fu et al. extracted the extracellular matrix from em-
bryoid bodies (e-ECM) derived from the H9 ESC line
[45]. This human-derived ECM consisting of fibronectin,
laminin and collagen type IV, proved to be a viable
method for xeno-free propagation of hESCs used to gen-
erate a xeno-free autologous feeder-free culture system
for long term culture of the H9 hESC line. The hESCs
were successfully maintained for 20 passages on this
ECM substrate in TeSR2, a chemically defined serum-
free and animal protein free medium [65,66]. Spontan-
eous differentiation in hESCs cultured on e-ECM wasmarkedly less than on Matrigel, suggesting a more sup-
portive environment. This xeno-free culture model was
also successfully used for terminal differentiation of the
hESCs in to keratinocytes for potential therapeutic appli-
cation [67]. Human placenta–derived ECM has also
been successfully used for hESC culture [68]. Cultures
showed genetic stability after 40 passages and differenti-
ation potential of the stem cells was retained.
These studies with extracellular matrix have been in-
strumental in identifying biomolecules involved in stem
cell renewal. Inconsistencies in ECM preparations even
if of human origin, do however still present a problem.
Certainly, use of chemically defined matrices and recom-
binant proteins based on ECM may be a more reliable
approach towards xeno-free culture of therapeutic grade
hESC lines. Xu and colleagues analyzed the individual
components of Matrigel and determined that not all are
equally effective for sustaining undifferentiated growth
of ESC lines [6]. Laminin appeared to be superior to fi-
bronectin and collagen IV for feeder-free growth of stem
cells in MEF-conditioned medium [6]. Others have suc-
cessfully used human fibronectin with bFGF and TGFβ
to culture hESC for over 180 days [69]. Beattie et al. [51]
showed that medium supplementation with Activin
could be used to eliminate the need for MEF cell condi-
tioned medium. Successful propagation of hESCs in a
serum and xeno-free medium, TeSR1 using a combin-
ation of human matrix components collagen IV, laminin,
vitronectin and fibronectin as a substratum marked a
significant milestone in the development of clinically
compliant hESC culture models [66,70]. This culture
system allowed derivation of a karyotypically normal
hESC line (WA-15) and also the undifferentiated propa-
gation of H1 and H9 stem cells under defined conditions
without animal products. Inclusion of Rho kinase inhibi-
tor (ROCK) in the serum free medium helped prevent
apoptosis in individual cells at passaging.
Laminin with its role in cell adhesion has been exten-
sively studied. Rodin et al. described a xeno-free system
for hESC and hiPSC cultivation using a recombinant
form of human laminin-511 with a defined medium,
TeSR1 [71]. This serum-free culture system allowed
hESC cell renewal with genetic stability for 4 months (20
passages). Miyazaki tested different recombinant human
laminin isoforms for their ability to serve as scaffolds for
hESC cultivation [72]. Laminin isoform binding to integ-
rin receptors α6β1 on hESC appeared to be integral to
triggering signaling pathways necessary for continuous
self-renewal. Recombinant human laminin isoforms LM-
111, 511 and 332 supported hESC adhesion and undif-
ferentiated cell growth. Further studies showed that even
fragments of different recombinant laminin isoforms
(LM E8’s) if they contained integrin binding capacity
could be used for hESC culture [73]. LM 511-E8 was in
Table 1 Feeder-free culture systems using extracellular matrix (ECM) proteins or biological substrates
System description/substrate Cell type Medium/supplements SF1 CD2 XF3 Culture period Ref.
Matrigel-mouse hESC MEF –CM4 (basal medium
DMEM+ KSR5) bFGF
Y N N 180 days [6]
Matrigel-mouse hESC/ DMEM/F12 Y N N 20 passages [102]
hiPSC Dorsomorphin, IWP-2, bFGF,,
TGF-β1, Activin
ECM from embryoid body (e-ECM) hESC TeSR2 Y Y Y 20 passages [65]
Human fibronectin hESC DMEM/KSR Y N N >47 passages [69]
bFGF,, TGF-β1 (+/− LIF) >180 days
Laminin hESC DMEM/KSR Y N N >20 passages [51]
bFGF, Activin
Laminin,vitronectin, fibronctin and collagen
IV (defined human ECM)
hESc TeSR1 Y N Y 11–25 passages [70]
Human placental ECM hESC XF medium -Human plasma extract,
with DMEM/F12 base, bFGF, TGFβ
N N Y 39 passages [68]
Laminin isoforms 111,332,511 hESC/ MEF –CM (basal medium DMEM+ KSR5) N N N 10 passages [72]
hiPSC bFGF
Laminin E8 fragments (LM-E8) hESC/ mTeSR1, Y N N [74]
hiPSC StemPro, Y N N 10–30 passages
TeSR2 Y Y Y
E-cadherin hESC mTeSR1 Y N N >90 days [79]
hiPSC
Laminin-511 hESC TeSR1 Y N Y 20 passages [71]
Laminin-521/E-cadherin matrix hESC mTeSR1, Y N N 35 passages [80]
hiPSC TeSR2, Y Y Y 12–15 passages
Vitronectin hESC mTeSR1 Y N N 10 passages [82]
Vitronectin- truncated hESC E8 medium Y Y Y >25 passages [83]
hiPSC
Fibronectin,, laminin and vitronectin hESC DMEM/F12 +/− bFGF Y Y Y >24 passages [87]
Wnt/ID8
Recombinant human vitronectin hESC/ E8 medium Y Y Y >30 passages [85]
Alginate microencapsulation hESC MEF-CM (basal medium DMEM//KSR) Y N N 14 days [126]
Alginate encapsulation of hESC on bFGF Y N N 19 days
Matrigel coated microcarriers
Aliginate-chitosan scaffold-3D hESC DMEM/F12 + KSR + FBS + bFGF Y N N 21 days [114]
Alginate-chitosan microfiber scaffold-3D hiPSC mTeSR1 Y N N 10 passages [115]
ROCK inhibitor
Alginate encapsulated hESC DMEM + KSR + bFGF Y N N >260 days [116]
Nanofibrillar cellulose hESC mTeSR1 Y N N >26 days [117]
Aggregates/ in suspension Fibronectin
and laminin present
hESC Neural basal medium.Neutrodoma-CS Y N Y >10 weeks [128]
bFGF, Activin, Neurotrophins BDNF,
NT3, NT4
Aggregates in suspension hESC mTESR1 Y N N 20–50 passages [131]
Polymer to prevent fusion/ hiPSC/ StemPro Y N N
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Table 1 Feeder-free culture systems using extracellular matrix (ECM) proteins or biological substrates (Continued)
DE-53 Matrigel coated cellulose microcarrier hESC mTeSR1 Y N N 25 passages [125]
StemPro Y N N
Artificial spider silk + vitronectin hESC/ Nutirstem XF/FF Y N Y >30 passages [93]
hiPSC
1SF serum –free medium.
2CD chemically defined medium (excludes any media containing BSA or HSA fraction due to their unknown and variable composition).
3XF xeno-free, no animal components in medium or culture system.
4MEF-CM mouse embryonic fibroblast conditioned medium.
5KSR knock out serum replacement protein.
Desai et al. Reproductive Biology and Endocrinology  (2015) 13:9 Page 6 of 15fact found to be superior to Matrigel or whole laminin
isoforms in promoting cell adhesion and proliferation of
stem cells. Stem cells could be cultivated under xeno-
free conditions in a chemically defined medium (TeSR2)
on the LM511-E8 coated substrate for over 30 passages
and retained pluripotency as well as a karyotypic stability.
The smaller size of LM-8 s as compared to whole laminin
simplifies manufacturing the recombinant product makingTable 2 Synthetic substrates for hESC culture
System description/substrate Cell type Medium/su
Synthetic acrylate surfaces (PAS) with peptides:
Vitronectin, bone sialo protein












Alkanethiol with heparin binding proteins hESC mTeSR1
Rock inhibi
PMVE-alt-MA8 hiPSC StemPro
APMAAm9 hydrogels hESC mTeSR1
Polyethylene glycol hydrogels (PEG) hESC DMEM/F12
bFGF
Hillex10 microcarrier//suspension culture hESC KSR-XF 10
BRASTEM,
bFGF
1SF serum –free medium.
2CD chemically defined medium (excludes any media containing BSA or HSA fractio
3XF xeno-free, no animal components in medium or culture system.
4Synthemax acrylate surface coated with peptide derived from vitronectin.
5PMEDSAH Poly [2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) ammonium hyd
6MEF-CM mouse embryonic fibroblast conditioned medium.
7Human cell conditioned medium.
8PMVE-alt-MA poly (methyl vinyl ether-alt-maleic anhydride.
9APMAAm aminopropylmethacrylamide—.
10Hillex polystyrene beads modified with cationic trimethyl ammonium.it more cost-effective. Nakagawa and colleagues reported
better attachment of hESC and hiPSC dissociated in to
single cells using StemFit media with laminin 511-E8
matrix [74].
E-cadherin, another cell adhesion molecule that binds
to the integrin α6β1 also plays a role in cell:cell binding
[75]. Poor survival and hESC death after dissociation
into individual cells is due to a disruption of E-cadherinpplements SF1 CD2 XF3 Culture period Ref
Y N Y >10 passages [89]
1
Y N N 10 passages [90]
Y N N 10–20 passages [91]
Y Y Y
Y Y Y
F Y N Y




Y N N >17 passages [92]
tor
Y N N 5 passages [94]
Y N N 20 passages [95]
+ KSR N N N 9 days [118]
Y N Y 6–14 days [123]
Y N Y
n due to their unknown and variable composition).
roxide]—.
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hiPSC cells on plates coated with E-cadherin fused with
the IgG FC domain [79]. This feeder-free system with a
defined medium, TeSR1 was effective as a substitute for
Matrigel. The matrix promoted adhesion and both types
of pluripotent stem cells (hiPSC and hESC) retained
their stem cell attributes for over 90 days in culture.
Supplementation of culture media with E-cadherin in
combination with recombinant laminin isoform 521 in-
creased efficiency of hESC line derivation from individ-
ual blastomeres as well as the ICMs of blastocysts in
chemically defined media under xeno-free conditions
[80]. This vital work provides a clinically compliant sys-
tem for the derivation of new stem lines for regenerative
medicine. The E-cadherin/laminin 521 based culture sys-
tem also allowed robust proliferation of hiPSC cells
under xeno-free conditions. A cocktail of specific kinase
inhibitors along with bFGF may also be beneficial for
propagating single stems cells under feeder-free chem-
ically defined conditions [81].
Amongst ECM components, vitronectin is another
protein that has emerged as a promising substratum for
long term culture of hESC cell serum-free conditions in
defined media [82-85]. Recombinant vitronectin was
able to effectively replace Matrigel as a substrate for
hESC culture in a defined medium [82]. Chen et al. de-
vised a simplified culture system for hPSC using a trun-
cated recombinant vitronectin coating and a chemically
defined, xeno-free and albumin-free medium known as
Essential 8 (E-8) [83]. This represents a significant ad-
vancement in the movement towards clinically compli-
ant culture models for stem cell applications. Hasegawa
et al. [84] identified two small chemical molecules that
could replace bFGF in culture media and still sustain hu-
man stem cell growth [84]. These molecules are modula-
tors of the Wnt/β-catenin signaling pathway [86-88].
Based on molecular clues present in the environment,
this pathway can drive hESC cells towards continued cell
renewal as well as differentiation. The combination of
Wnt modulators with ECM-based substrata (vitronectin,
laminin or fibronectin) allows culture in a chemically de-
fined media without exogenous supplementation with
bFGF or TGFβ.
Synthetic substrata for stem cell culture have also been
investigated as alternatives to complex ECM matrices.
Synthetic peptide acrylate surfaces (PAS) constructed by
conjugating peptides derived from the biologically active
region of extracellular matrix proteins can sustain the
self-renewal and pluripotency of hESCs for over 10 pas-
sages in a xeno-free defined medium X-Vivo 10 [89]. In
this study, Melkoumian et al. tested acrylate surfaces
with bound peptides from laminin, vitronectin, fibro-
nectin or bone sialoprotein. PAS with vitronectin or
bone-sialoprotein derived peptides showed the bestfunctionality. These cultured stem cells were also cap-
able of directed differentiation in to cardiomyocytes.
Corning Synthemax Surface, a synthetic acrylate sur-
face with RGD peptide containing sequence from
vitronectin was shown to support the expansion and
directed differentiation of human induced pluripotent
cells in defined medium [90]. More recently, investiga-
tors demonstrated that Synthemax could also be used
for the efficient expansion of not only colonies but also
single dissociated hPSCs in several serum-free and
xeno-free culture media like TESR2, Nutristem XF and
PSGro [91].
Klim et al. [92] systematically screened 18 bioactive
peptides bound to different substrata to identify peptide
surfaces that could sustain hESC growth under defined
conditions. Surfaces with the heparin binding pepetide
GKKQRFRHRNRKG isolated from vitronectin were
shown to facilitate hESC adhesion and proliferation [92].
This peptide was demonstrated to function by interacting
with hESC cell- surface glycoasoaminoglycans. Interest-
ingly, surfaces prepared with only peptides containing the
core integrin binding motif (arginine-glycine-aspartic acid,
RGD) were inadequate for sustained hESC culture.
Wu et al. recently described a novel synthetic material
based on spider silk proteins as a suitable substrate for
hESC culture [93]. This artificial matrix composed of re-
combinant miniature spider silk protein, 4RepCT (~3000
base pairs) can be easily manufactured and formed into
films, fiber or foam under sterile conditions. Variants
of the matrix were created by fusing it with biological
peptides derived from laminin or vitronctin. The inves-
tigators cultured both hESC and hiPSC lines on
4RepCT-vitronectin films in xeno-free defined medium
Nutristem for over 30 passages without loss of stem
cell attributes. The cultured hPSC had the capacity to
form teratomas in vivo and to undergo directed differenti-
ation into endoderm and also cardiomyocytes in vitro.
The properties of the biomatrix allowed for 2-D as well as
3-D culture.
The cost of peptide synthesis, stability of substratum
with attached biological molecules and anticipated diffi-
culties with scale up during manufacture has triggered
interest in establishing purely synthetic surfaces for
serum-free culture of hESC. This has proved to be par-
ticularly challenging. Numerous polymer based synthetic
surfaces such as PMEDSAH (poly [2- (methyacryloyoxy)
ethyldimethyl-(3-sulfopropyl) ammonium hydroxide]),
PMVE-alt-MA (poly (methyl vinyl ether-alt-maleic an-
hydride)), HIT9 and APMAAm (aminopropylmethacryla-
mide have been tested [89,94-99]. Amongst the tested
synthetic polymers, PMEDSAH [98] and APMAAm [95]
appear to have the most promise, supporting growth of
several hESC lines for at least 20 passages with retention
of pluripotency and karyotypic stability.
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molecular modulators Transition towards xeno-free
culture systems has necessitated the formulation of new
media suitable for cultivation of stem cells under serum-
free conditions [66,70,83,100,101]. Basal medium such
as DMEM/F12 containing amino acids, glucose, vita-
mins, insulin, transferrin, selenium in a balanced salt so-
lution has been the foundation for many of the in-house
as well as commercially available culture media for hESC
cultivation. Cholesterol, lipids, GABA, pipecolic, ascor-
bic acid and β mercaptoethanol are also often included.
The compositions of several commercially available
media are shown in Table 3. In the absence of serum, all
either contain or require bFGF supplementation at con-
centrations ranging from 20–100 ng/ml. Other select
growth factor/cytokine additives used in the various
media formulations are TGFß, Activin A, LIF, stem cell
factor (SCF) and a structurally similar cytokine FLT3
(FMS-like tyrosine kinase). Under xeno-free conditions,
suppression of signaling by bone morphogenetic protein
(BMP) can prevent loss of stem cell pluripotency [59,62].
BMP-antagonists like Noggin when included in culture
media work synergistically with bFGF to maintain stem
cell homeostasis. Another inhibitor of BMP signaling,
dorsopmorphin along with inhibitors of the Wnt signal-
ing pathway also work to suppress spontaneous differen-
tiation in pluripotent cells in a xeno-free culture
medium [102].
Commercial protein supplements like KnockOut –
Serum Replacement (KSR) are often used in culture sys-
tems to replace fetal bovine serum but do in fact still
contain animal derived serum albumen. Only a few of
the media described are completely xeno-free with hu-
man serum albumen (HSA) as a protein source in lieu of
bovine serum albumen (BSA). However, since HSA is
extracted from different pools of donor serum there are
batch-to-batch variations. Also HSA manufacturing
guidelines only require a purity of ≥96% so most com-
mercial preparations for cell culture contain other un-
defined plasma proteins and contaminants from the
purification process. To technically be classified as a
“chemically defined medium”, all constituents of the
medium and their concentrations must be known
[103,104]. Media formulations with BSA or HSA ex-
tracted from plasma, introduce contaminants that may
not always be precisely controlled and therefore do not
meet this strict definition. Confusion over this termin-
ology is evident from the literature. Numerous media
that were developed with bovine and/or human albumen
in lieu of serum have early on been referred to as “de-
fined or “chemically defined” (as compared to serum
containing media), if all other media components were
quantifiable. Recombinant HSA is now often substituted
for serum derived HSA in designing new chemicallydefined media. Table 3 describes commercially available
media for serum-free culture of hESCs and information
on their composition. Several xeno-free chemically de-
fined media are currently on the market such as TeSR2
and PSGro with recombinant HSA, as well as Essential 8
(E8) and TESR-E8 which do not contain albumen. X-
Vivo 10, a defined medium, with recombinant growth
factors and highly purified, traceable pharmaceutical
grade HSA is also a part of this grouping.
Although considerable progress has been made in the
design of chemically defined xeno-free media, cell pas-
sage, and fold-expansion may be limited by the quality
of culture supplements and their stability in culture.
Daily replenishing of media is often recommended when
using chemically defined media and this can be both
costly and labor intensive.
3D Culture models Although chemically defined ECM
based matrices have helped advance the design of xeno-
free hESC culture models, they may still be limited in
their ability to physiologically mimic the in vivo stem cell
niche. Studies indicate distinct differences in cell signaling
and behavior in cells grown in 2-D versus 3-D culture
[105-107]. During embryogenesis, inner cell mass cells are
embedded within a dynamic 3D stem cell niche, which
helps direct both self-renewal and differentiation via the
presentation of specific cell signaling molecules, regulation
of matrix stiffness, and the establishment of cytokine gra-
dients [108]. While the exact biomolecular composition of
this native hESC environment has not been fully defined
to date, it is likely that 2D systems will prove inadequate
in functionally mimicking the in vivo microenvironment,
ultimately restricting their ability to optimally support
downstream differentiation applications. Bioengineered 3-
D scaffolds offer an opportunity to modulate stem cell be-
havior in vitro to more closely resemble that occurring
in vivo [109-112].
Numerous substrates for 3-D culture have been ex-
plored and tested. As a biomaterial, hydrogels are per-
haps the most versatile and have been used in a variety
of engineering applications. Hydrogels are a network of
polymer chains either of natural or synthetic origin that
are very absorbent and flexible due to high water con-
tent, thus resembling natural matrices. Hyaluronic acid
(HA) is a glycosaminoglycan (GAG) and a primary com-
ponent of in vivo extracellular matrices, making it par-
ticularly attractive in designing 3-D scaffolding for stem
cells. GAG’s are known participators in receptor signal-
ing complexes, cell-cell adhesion, and cell-matrix inter-
actions. HA-hydrogel architecture and rigidity can be
easily manipulated. HA encapsulated hESCs were shown
to retain pluripotency for 20 days in culture and the
need for continuous stem cell passaging was eliminated
[113]. The hydrogel scaffolds also allowed hESC to be
Table 3 Commercially available serum-free media for hESC and hiPSC culture
Medium Source (Catalog#) Basal medium/protein/select supplements XF CD
ESF Cell Science & Technology ESF basal medium// FAF-BSA conjugated with oleic acid N N
FGF-2, LIF, insulin, transferrin, selenium, ascorbic acid,
β-mercaptoethanol
mTeSR1 Stemcell Technologies (#05850) DMEM/F12/BSA N N
bFGF, TGFβ, insulin, transferrin, cholesterol, lipids, pipecolic
acid, GABA, β-mercaptoethanol
TeSR1a Stemcell Technologies DMEM/F12 /HSA Y N
bFGF, TGFβ, insulin, transferrin, cholesterol, lipids, pipecolic
acid, GABA, β-mercaptoethanol
TeSR2 Stemcell Technologies (#05860) DMEM/F12 // with recombinant HSA Y Y
bFGF, TGFβ, insulin, transferrin, cholesterol, lipids, pipecolic
acid, GABA, β-mercaptoethanol
E8 Stemcell Technologies (#05940) DMEM/F12 Y Y
bFGF, TGFβ, insulin, transferrin, selenium, ascorbic acid
TESR-E8 Stemcell Technologies (#05940) Medium based on E8 formulation Y Y
Nutristem XF/FF Stemgent (#010005) Basal medium/ HSA Y N
bFGF, TGFβ, insulin, transferrin
StemPro Life Technologies (#A1000701) DMEM/F12/BSA N N
bFGF, TGFβ, Activin, transferrin, LR3-IGF1, HRG1β
X-Vivo 10 Lonza (#04380Q) Basal medium/ HSA-pharmaceutical grade purification Y Y
bFGF, hFLT3, transferrin, β-mercaptoethanol
Neutrodoma-CS Roche (11363743001) Neural basal medium.Neutrodoma-CS/HSA Y N
bFGF, Activin, Neurotrophins
PluriStem Millipore (#SCM130) DMEM//F12, HSA Y N
Activin-A, TGFβ1, b-FGF, lipids, insulin, transferrin, selenium
dorsomorphin (DM), IWP-2
HyClone HyCellStem GE healthcare life sciences (#SR30003.KT) DMEM//F12; BSA Y N
bFGF, insulin,
PSGro Stem RD (#SC500M-1) DMEM//F12 with recombinant HSA Y Y
bFGF, TGFβ1, insulin,transferrrin, selenium, lipids
StemFit Ajinomoto Co. Basal medium, HSA Y N
bFGF
Table 3 contains a list of commercially available media that can be used for serum free culture of HESCs and hiPSCs.
XF xeno-free, no animal components in medium.
CD chemically defined medium (excludes any media containing BSA or HSA fraction due to their unknown and variable composition).
aOriginal formulation similar to mTESR1 but with HSA fraction. Replaced by TESR2 with recombinant form of HSA.
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release from the hydrogel necessitated enzymatic diges-
tion with hyaluronidase which may however impact
stem cell functionality in the long term. It should be
noted MEF-conditioned medium was still used in this
study.
Others have used a hydrogel scaffold composed of chi-
tosan, a deceatylated cationic polysaccharide and algin-
ate [114]. Investigators were able to show self-renewal
and characteristic hESC gene activity for 21 days in the
absence of feeder layers or conditioned medium. Direct
implantation of hESC-scaffold constructs in to miceresulted in teratoma formation, with immunohistochemi-
cal evidence of all three germ layers. Microfiber constructs
of chitosan-alginate also support hESC self-renewal under
chemically defined conditions [115]. The 3-D microfiber
culture model has the added benefit of allowing direct
cryopreservation in situ of encapsulated cells. To date
there has only been one report of hESC culture for more
than 30 days in a 3-D matrix. Using alginate hydrogels,
Siti-Ismail and colleagues [116] were able to maintain
hESCs in a pluripotent state for 260 days, without enzym-
atic treatment and repeated passaging of the cells. This
was accomplished using a basic stem cell maintenance
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bFGF supplementation.
A plant-derived nanofibrillar cellulose (NFC) has simi-
larly been used to create a flexible 3D environment
[117]. This hydrogel system utilized maintained stem
cells in culture as 3-D spheroids, under xeno-free and
feeder-free conditions in a defined medium, TESR. Pas-
saging was accomplished by enzymatically denaturing
the matrix and transferring the cells to new NFC plat-
forms every 7–12 days. The hESC could be maintained
undifferentiated as 3-D spheroids for 26 days after which
teratoma formation was observed. The undifferentiated
hESCs were karyotypically normal and expressed mRNA
for all pluripotency markers.
Synthetic polymers are especially valuable for 3-D scaf-
folding, offering the advantage of versatility. Microfabri-
cation techniques can be used to generate scaffolds with
specific chemical signals immobilized on the matrix. As
discussed earlier, combining matrices with tissue-specific
bioactive molecules such as cell-adhesion proteins,
growth factors and peptides are particularly promising.
Derivatives of polyethylene glycol (PEG) combined with
tissue-specific bioactive molecules such as cell-adhesion
proteins, growth factors and peptides are particularly
promising. The presentation of physiologically relevant
signals allows the hESC microenvironment to be tailored
towards self-renewal or differentiation as needed. PEG
hydrogel constructs cross-linked with matrix metallo-
proteinase (MMP)-sensitive peptides and coupled with
integrin-specific adhesion ligands are able to sustain the
pluripotency of mouse and human stem cells [118,119].
The 3-D PEG-based scaffolds supported the expansion,
self-renewal and differentiation potential of pluripotent
hESC lines H1, H9 and Novo, under feeder-free condi-
tions in culture medium supplemented with bFGF and
knock-out serum replacement. Increased mRNA expres-
sion of stemness- related genes were detected in hESCs
after 3-D culture on PEG scaffolds as compared to 2-D
culture on MEF feeders or in Matrigel.
Suspension culture of hESCs on microcarriers (MC)
has also been used to create a pseudo 3D microenviron-
ment that can be easily manipulated to direct cells
towards undifferentiated proliferation or directed cell
differentiation [94,104,120-127]. Microcarriers allow easy
scale up in bioreactors to increase total stem cell pro-
duction. Cell adhesion to microcarriers can be increased
by altering their surface. hESC could be cultured on
Matrigel coated cellulose beads in serum-free mTeSR
and Stem Pro media for 20 passages without loss of stem
cell characteristics [125]. Marinho and colleagues [123]
developed a serum-free xeno-free culture system for hESC
culture using polystyrene microcarrier spheres positively
charged with triethyl-ammonium groups (Hillex II) and a
defined medium BRASTEM supplemented with bFGF.High growth rate of stem cells and retention of pluripo-
tency was demonstrated after six days in culture. Although
promising, serial passaging of pluripotent hESCs on
microcarriers over a much longer time interval are neces-
sary to validate this xeno-free culture model for any clin-
ical application. One of the problems with MC based
suspension culture has been the tendency of hESC cells to
aggregate resulting in multi-bead clusters with low speed
agitation in the bioreactors. High levels of agitation re-
sulted in shear stress which was also detrimental to con-
tinued propagation hESC cultures.
Suspension culture of hESCs without the use of coat-
ings or microcarriers is also possible [128-131]. Aggre-
gate cell suspension culture of hESCs has been shown to
be a particularly favorable culture system for embryoid
body formation, eliminating the need for extraneous
scaffolds [130]. Steiner and colleagues devised a culture
model for generating hESC lines from clusters of inner
cell mass cells kept in suspension culture. The initial
ICM were extracted from embryos using a laser. They
were able to generate 3 new hESC lines under xeno-free
conditions in defined medium supplemented with lam-
inin, fibronectin, bFGF, Activin A and neurotrophins
BDNF, NT3 and NT4. The new stem cell lines retained
pluripotent characteristics even after 10 weeks in cul-
ture, were capable of forming all 3 germ layers and could
undergo directed differentiation in to neural spheres.
Loss of cell viability during passaging can however result
in lower expansion rates in suspension culture as com-
pared to that typically observed with adherent cell cul-
ture models. Wang et al. developed a scalable xeno-free
and clinically compliant culture system for hiPSC suit-
able for both suspension and adherent culture [85]. This
was achieved in the chemically defined medium, E8 that
consists of just 8 components. hiPSC maintained pluri-
potency in culture expressing all stem cell markers and
exhibiting karyotype stability after more than 30 pas-
sages. The induced pluripotent cells could be directed
towards differentiation into hematopoetic cells and
showed teratoma formation upon injection in to mice.
Demonstrated efficacy combined with its simplicity
make this model especially attractive and cost-effective
for large scale production of hiPSCs. A 3-D sphere cul-
ture system using a methylcellulose polymer to suppress
fusion of aggregates was recently described and may
help to further optimize the suspension culture model
[131]. Investigators tested the system with both mTESR1
and StemPro medium, with similar results as regards re-
tention of pluripotency.
Summary
Considerations in selection of optimal matrices for stem
cell culture should also include ease of stem cell release
for passaging, stability over time and compatibility with
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but is especially critical if substrates containing bio-
logical components like growth factors and peptides are
to be used. Another consideration is the cost of using
exclusively xeno-free synthetic media, recombinant
growth factors and other additives. Culture design must
also allow for large-scale propagation to meet the stem
cell dosages needed for patient treatment cycles. The
ability to effectively direct terminal differentiation of
stem cells under these same xeno-free conditions is also
of paramount importance in developing future therapeutic
applications.
Therapeutic application and clinical trials
Currently, the FDA requires all hESC (and hiPSC) lines
intended for use in clinical trials to be developed in
compliance with current Good Manufacturing Practices
(cGMP) and in accordance with the Guidelines for the
Clinical Transplantation of Stem Cells [132]. Manufac-
turing process, reagents, validation of methodology, en-
vironmental controls, safety etc. must all be monitored
and documented in detail in accordance with cGMP reg-
ulations. Terminal differentiation of the hPSCs in to the
desired cell type for treatment needs also to be per-
formed under stringent cGMP compliant conditions to
avoid possibility of tumor formation on transplant. De-
tailed characterization of the cells, demonstration of
karyotype stability and function in animal models are
necessary prior to any therapeutic application. While
regulations do not preclude the use of animal derived
products when deemed necessary, it is widely believed
that xeno-free culture is the only way to limit the poten-
tial risks of hESC transplantation rejection. Most of the
hESC lines currently in use have in fact been exposed to
potentially immunogenic and pathogenic animal compo-
nents at some point, whether during their isolation,
propagation, or both. To date, only a few groups have
produced hESC lines derived under these conditions
[15,133,134]. Reproducibility and reliability will be key
for any type of therapeutic application. Chemically de-
fined media using only recombinant supplements may
be the surest way to maintain the level of consistency
and safety desirable in the clinical setting.
FDA approval of the first clinical trials of hESCs for
treatment of spinal cord injury and macular degener-
ation in 2009 marked the beginning of a new era in re-
generative medicine [135-141]. Geron Corporation a
biotechnology firm based in California planned to inject
patients with GRNOPC1, a product developed from hu-
man embryonic stem cells. The basis for this treatment
was a technique for development of oligodendrocytes
from hESC by investigators at the University of California
[142]. The first patient treated in October 2010, after a
spinal cord injury from a car accident received 1.5 millionoligodendrocyte precursor cells. The planned enroll-
ment for the trial was 10 patients but the study was un-
expectedly discontinued after the treatment of only 3
more patients. High cost and difficulties producing the
necessary dosage of stem cells under clinically compli-
ant conditions may have been the cause. No official
data were ever published. However preliminary results
indicated that while patients did not experience ad-
verse effects, the treatment did not result in any no-
ticeable improvement to spinal injury or neurological
condition.
Advance Cell Technology (Marlborough, Massachu-
setts) has two on-going clinical trials. The first is for
Stargardt’s Macular Dystrophy, which results in blind-
ness from degeneration of the retinal epithelium and loss
of photoreceptor cells. The second is for age-related dry
macular degeneration. Retinal pigment epithelial cells
(RPE) derived from hESC were used to restore the
degenerative retinal epithelial monolayer. Scwartz et al.
published the first report on transplantation of hESC-
derived RPE in to a human patient in 2012 [138]. A dos-
age of 50,000-200,000 cells was hESC-derived RPE were
administered. Initial results were promising with no in-
dication of immune mediated graft rejection, teratoma
formation or hyper proliferation at four months post-
transplantation. Early data also suggested some improve-
ments in visual acuity.
Stem cell therapy for treatment of Type I Diabetes is
the newest arena for therapeutic use of hESC cells. Loss
of insulin secreting cells in the pancreas is the cause of
the disease. In August 2014, a diabetes clinical trial with
hESC derived islet cells was approved [143]. The company
Viacyte (San Diego, California) just recently reported suc-
cessful surgical transplantation of their product VC-01 in
to the first of 40 patients enrolled in the trial [144]. With
this therapy, pancreatic precursor cells (PEC-01) encapsu-
lated in a porous cell-impermeable membrane are placed
under the skin.
Minimizing immune rejection and thus the longevity
of transplanted cells is also a priority for successful use
of hESC based therapies. Besides immune response from
any animal derived products, there is the risk of trans-
plantation rejection due to HLA or ABO blood group
antigen mismatch. Undifferentiated hESC’s have been
shown to express low levels of MHC class I molecules,
which are up-regulated during differentiation [145]. The
issue of donor-recipient mismatch may ultimately have
to be dealt with through knockdown of MHC molecules
on donor stem cells or establishment of a large number
of hESC lines to allow for HLA and ABO matching
[146,147]. Another intriguing possibility is the banking
of ICM cells from embryos donated for research to allow
for future derivation of stem cell lines with the desired
match [148].
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Developing effective cell based regenerative therapies re-
main a challenge. Xeno-free culture models using extra-
cellular matrices, biosynthetic surfaces and chemically
defined media to create therapeutic grade hESC repre-
sent an important stepping stone in expanding such
therapies. More data is still needed on the continued
functionality of hESC cells after long term culture and
continued passage in these new culture models. In depth
analysis of cellular level mechanisms involved in con-
tinuous self-renewal as well as terminal differentiation
will ultimately be necessary to truly harness the power
of these pluripotent cells.
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